Coated versus non-coated flow diverter stents for intracranial aneurysm embolization: a propensity score-matched cohort study - 20/11/26
, Jildaz Caroff a, c, Fernanda Rodriguez-Erazú a, Ignacio Molina Diaz a, Mohamed Ismail a, Andrés Silva-Pozo a, Hugo Cadilha a, Taisuke Akimoto a, Daniel Claudiu Malita b, d, Léon Ikka a, Vanessa Chalumeau a, Vincent Plaforet a, Laurent Spelle a, e, Jonathan Cortese a, eHighlights |
• | Coated vs non-coated flow diverters in a propensity score-matched cohort. |
• | Primary endpoint - any thromboembolic event: 5.3% coated vs 14.9% non-coated. |
• | Absolute risk difference -9.6% (95% CI -18.1 to +0.9), p = 0.08. |
• | Secondary endpoints: neointimal hyperplasia, occlusion and clinical outcomes similar. |
• | Larger multicenter studies are needed to confirm a benefit of coated flow diverters. |
ABSTRACT |
BACKGROUND AND PURPOSE |
Coated flow diverters (FDs) were developed to reduce thromboembolic complications and to potentially facilitate endothelialization. We compared coated versus non-coated FDs for intracranial aneurysm embolization.
MATERIALS AND METHODS |
We retrospectively analyzed 286 consecutive unruptured aneurysms in 262 patients treated with FDs between 2018 and 2024 from a prospectively maintained single-center database. Ten aneurysms treated under single antiplatelet therapy within a randomized trial were excluded before matching, so that the propensity score model was built within a uniformly dual-antiplatelet population. The primary outcome was periprocedural thromboembolic events; secondary outcomes were hemorrhagic complications, FD-related and permanent morbidity, complete occlusion and relevant neointimal hyperplasia (NIH). Matching was performed 2:1 on patient demographics, cardiovascular risk factors, aneurysm location, morphology and size, neck coverage and follow-up duration.
RESULTS |
After matching, 114 non-coated and 57 coated aneurysms were analyzed. Thromboembolic events were less frequent in the coated group without reaching statistical significance (5.3% vs 14.9%; risk difference −9.6%, 95% CI −18.1 to +0.9; relative risk 0.35, 95% CI 0.11–1.15; p=0.08). Rates of relevant NIH (>25%) were similar (17.5% vs 13.2%, p=0.44), as were complete occlusion rates (77.2% vs 71.9%, p=0.46). FD-related and permanent morbidity did not differ significantly.
CONCLUSIONS |
In this exploratory analysis, coated FDs showed a numerically lower rate of thromboembolic events that did not reach statistical significance, with no significant differences in NIH or in angiographic and clinical outcomes. Further development of coating technologies, along with larger multicenter studies and longer follow-up, is needed to better define their potential to improve outcomes.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Keywords : Flow diverter, Intracranial aneurysm, Coating, Endovascular treatment
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
